Nuocheng Jianhua (09969): Positive top-line results of phase II adaptive study of SOFICITINIB (ICP-332) for the treatment of non-segmental vitiligo.

The Zh tng financial news app reported that Nuocheng Jianhua (09969) announced that its self-developed new generation oral tyrosine kinase 2 inhibitor soficitinib (ICP-332) has successfully reached its primary endpoint in the ongoing phase II adaptuve clinical study for adult patients with non-segmental vitiligo.